Announcement of Glyxambi launch popularizes Jardiance & Trajenta
As it was recently known a Boehringer Ingelheim diabetes treatment combined by DPP-4 and SGLT-2 inhibitors, ‘Glyxambi’ applied for commercialization approval from the Ministry of Food and Drug Safety(MFDS), ‘Trajenta(generic name: linagliptin)’ and ‘Jardiance(generic name: empagliflozin)’ have at...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
